about
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.Optimal Use of Vaccines for Control of Influenza A Virus in SwineNovel approaches to develop Rift Valley fever vaccinesSelf-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic NanoparticlesSindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural PolyproteinSelf-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In VivoComparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in miceHaemagglutinin and nucleoprotein replicon particle vaccination of swine protects against the pandemic H1N1 2009 virus.Viral vector-based influenza vaccines.Vaccine development for protecting swine against influenza virus.Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.Rapid development of an efficacious swine vaccine for novel H1N1Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.Development of replication-competent viral vectors for HIV vaccine delivery.Double subgenomic alphaviruses expressing multiple fluorescent proteins using a Rhopalosiphum padi virus internal ribosome entry site elementA chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measlesCharacterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeAn alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerVirus-vectored influenza virus vaccines.Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis virusesVaccines: past, present and future.Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.Development and characterization of an enhanced nonviral expression vector for electroporation cancer treatment.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in SituProspects for immunisation against Marburg and Ebola viruses.Detection of African Swine Fever Virus Antibodies in Serum and Oral Fluid Specimens Using a Recombinant Protein 30 (p30) Dual Matrix Indirect ELISAT cell-mediated immunotherapy of metastases: state of the art in 2005.Nonviral delivery of self-amplifying RNA vaccines.Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications.Intranasal delivery of vaccines against HIV.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivectorVenezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.De Novo Transcriptome Analysis Shows That SAV-3 Infection Upregulates Pattern Recognition Receptors of the Endosomal Toll-Like and RIG-I-Like Receptor Signaling Pathways in Macrophage/Dendritic Like TO-Cells.HIV/AIDS vaccines: a need for new concepts?
P2860
Q24796792-7EBE8B9A-125A-4AC2-BFB0-0B537C72304DQ26783503-342A5C7B-8EE9-44D2-A5ED-9D21F5E4ED05Q27027003-2E99C5CE-7AB4-4FA1-B498-9D53D6B24D7FQ27027078-A6F606E4-A4EA-4339-9744-4F45CC8F9616Q27473478-F537D4F8-B763-4024-A94D-F2A2BE169B37Q28654968-167A0738-4555-4B3A-94C9-9E3C93B90E4CQ28752489-8D62F119-D2A1-43B1-93B6-8BF5F318A886Q30354025-60052977-ECE6-4426-B083-A0B1904F51AFQ30390938-C252BC9F-8973-4D47-942A-ECD39D1268BCQ30424943-C3BCFA95-9E9F-41BB-8DF3-85E0607C0997Q33492290-E5EAF52A-CFE2-46A4-90B2-B7C857B38F50Q33520451-C884CB8F-9DBC-4DDF-A14C-1925E2B28E25Q33646948-CBFFA510-1C6D-4F4C-AF67-C6DAD1640D8FQ33694226-D8D81F95-DBAE-4E96-B8F5-96F2C513F7C8Q33750316-6D3B269D-807F-4D10-83C5-7AB4B82CE29CQ33769306-352EA7F0-5C41-4ACE-9A2C-F36B6CD77331Q33788861-49F59FC9-8F11-4BC8-8F1F-388A7D61E9F8Q33964113-6F985A33-CB9B-4640-A30B-C4B76FCA0E09Q34058118-C4C245DC-B81E-48E1-AFFB-A148B730A69AQ34090155-0C1283EA-7DD0-42B1-B091-06F8375F79FEQ34102268-3B98C2C8-DA26-409D-A063-6778F164AB36Q34261536-4655028E-6863-47EF-91C5-901C39B295FEQ34409178-002D3536-2956-406B-A2C9-8932D30B8D7AQ35034240-8344566C-8BDE-4E7D-8A58-AD5BC96E1D1FQ35184157-CCE0B998-8ACC-427E-9826-0D56520C6224Q35600305-A1E3D20E-4FAB-4B41-A739-A0B8CDBF89F5Q35826688-61752B34-93C6-4424-A01C-FFEE5E3A1664Q36088118-D3007570-9DE9-47CA-A443-6266BE44EC9CQ36128470-C9D4C1D7-286A-4638-B26D-3296F0F86229Q36210864-4096BD3E-4F90-452A-9147-9677779FDDB8Q36221799-BD56B802-9893-4CA0-A4E1-B92B64417568Q36377208-73FF3E76-9389-41C8-8FFF-EDE2D2064DCBQ36409054-0EAC889B-DCDE-4ED1-A91B-B708FDED1BA5Q36498186-7C8E74A3-9C33-4740-A6D7-5AFC1516B411Q36524157-C7EC8AD2-52F1-4A63-A02B-F1AB54D7FFADQ36716920-92CACA39-D105-4E00-B7FA-635F420802C8Q36751598-B3E2A017-2B45-4E0E-B39E-B66166060190Q36759944-56A87ED3-56C0-4A08-91C2-89B9E6C8B471Q36846041-0C7C6832-66BE-4A54-B855-73E9D313F036Q37344236-C60177F2-C0C5-4A72-B7A7-4FA5DCFA5382
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Alphavirus vectors and vaccination.
@ast
Alphavirus vectors and vaccination.
@en
Alphavirus vectors and vaccination.
@nl
type
label
Alphavirus vectors and vaccination.
@ast
Alphavirus vectors and vaccination.
@en
Alphavirus vectors and vaccination.
@nl
prefLabel
Alphavirus vectors and vaccination.
@ast
Alphavirus vectors and vaccination.
@en
Alphavirus vectors and vaccination.
@nl
P2093
P2860
P356
P1476
Alphavirus vectors and vaccination.
@en
P2093
Jonathan O Rayner
Kurt I Kamrud
Sergey A Dryga
P2860
P304
P356
10.1002/RMV.360
P577
2002-09-01T00:00:00Z